View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 28, 2022

Todos Medical, NLC Pharma reveal positive Phase II hospitalised Covid-19 trial data

In the trial's Part 2, 0% Covid-19 deaths were observed with Tollovir versus 22% in the placebo arm.

Todos Medical and NLC Pharma have reported that Tollovir met its primary and key secondary endpoints in a Phase II clinical trial to treat hospitalised patients with severe and critical Covid-19.  

Named Study NLC-V-01, the double-blind, placebo-controlled, randomised Phase II trial analysed the efficacy and safety of NLC-V (Tollovir) in adult subjects admitted to hospital due to Covid-19. 

The trial intended to randomise nearly 78 subjects into a 1:1 ratio and stratified by weight to receive either Tollovir or placebo, apart from the standard of care.

Participants requiring mechanical ventilation were given the randomised therapy using liquid syrup. 

In November last year, the companies concluded enrolment following the recruitment of 31 subjects to carry out an interim assessment to analyse Tollovir’s safety and efficacy.

The trial was carried out in two parts with Part 1 enrolling subjects from December 2020 to February last year when there were cases of Alpha and Beta variants of the SARS-CoV-2 virus.

Part 2 had subjects enrolled from May to November last year during the prevalence of the Delta variant. 

According to the positive interim results, Tollovir met its primary goal of lowering time to clinical improvement as well as various crucial secondary clinical endpoints, including a complete decline in Covid-19 deaths. 

Tollovir arm of Part 2 of the trial had an average decline of 2.7 days in time to clinical improvement, as assessed by the National Emergency Warning System 2 (NEWS2) versus placebo.

Furthermore, no cases of deaths linked to Covid-19 were reported in the Tollovir arm as against 22% in the placebo arm.

The Phase II trial was closed by the company early due to positive interim efficacy results. 

Todos Medical president and CEO Gerald Commissiong said: “We are extremely pleased with the results from this clinical study in the hospital setting of our dual mechanism antiviral and anti-cytokine oral drug candidate Tollovir.

“We have already begun preparing manufacturing for commercial quantities of Tollovir so that we will be able to deliver shipments in jurisdictions where we expect to be granted accelerated Emergency Use Authorization (EUA) and are in the process of fine-tuning our proposed Phase II/III clinical study protocol for hospitalised Covid-19 patients.”

Tollovir is an oral antiviral inhibitor of 3CL protease. It is also an anti-cytokine therapy candidate to treat nidovirus subcategory of coronaviruses comprising SARS-CoV-2, Covid-19, SARS-CoV-1, MERS and 229E.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy